School of Medicine
Showing 401-500 of 616 Results
-
Yasodha Natkunam, M.D., Ph.D
Ronald F. Dorfman, MBBch, FRCPath Professor of Hematopathology
Current Research and Scholarly InterestsMy research interests focus on the identification and characterization of markers of diagnostic and prognostic importance in hematolymphoid neoplasia.
-
Joel Neal, MD, PhD
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsI am a thoracic oncologist who cares for patients with non-small cell lung cancer, malignant mesothelioma, and other thoracic malignancies. I design and conduct clinical trials of novel therapies in collaboration with other researchers and pharmaceutical companies. These generally focus on two areas, 1) targeted therapies against particular mutations in cancers (for example EGFR, ALK, ROS1, HER2, KRAS, MET, and others) and 2) the emerging field of immunotherapy in cancer, using anti PD-1/PD-L1 therapies in combination with other agents, and also developing cellular therapies. I also collaborate with other researchers on campus to apply emerging technologies to cancer therapy, for example, circulating tumor DNA detection. Additionally, in my role as the Cancer Center IT Medical Director, I coordinate projects relating to our use of the electronic health record to improve provider efficiency and facilitate patient care.
-
Robert Negrin
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsOur labaratory focuses on the study of immune recognition by T and NK cells with special emphasis on graft vs host disease and graft vs tumor reactions. We utilize both murine and human systems in an effort to enhance graft vs tumor reactions while controlling graft vs host disease. We have developed bioluminescence models in collaboration with the Contag laboratory to study the trafficking of immune effector cells with a special emphasis on NK, T and regulatory T cells.
-
William Nelson
Rudy J. and Daphne Donohue Munzer Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsOur research objectives are to understand the cellular mechanisms involved in the development and maintenance of epithelial cell polarity. Polarized epithelial cells play fundamental roles in the ontogeny and function of a variety of tissues and organs.
-
Aaron Newman
Associate Professor of Biomedical Data Science
Current Research and Scholarly InterestsOur group develops computational strategies to study the phenotypic diversity, differentiation hierarchies, and clinical significance of tumor cell subsets and their surrounding microenvironments. Key results are further explored experimentally, both in our lab and through collaboration, with the ultimate goal of translating promising findings into the clinic.
-
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsWe conduct clinical trials and epidemiological, translational, and real-world studies of liver cancer, fatty liver (NASH, NAFLD), viral hepatitis B and C, liver cirrhosis, and liver transplant. We focus on risk identification for disease prevention and treatment for improvement of survival. We focus on sex, racial/ethnic, and socioeconomic disparities. We specialize in clinical trials, large international real-world consortium registry data, and large public/semi-public databases.
-
Dwight Nishimura
Addie and Al Macovski Professor, Emeritus
Current Research and Scholarly Interestsmedical imaging, magnetic resonance imaging
-
Garry Nolan
Rachford and Carlota Harris Professor
Current Research and Scholarly InterestsDr. Nolan's group uses high throughput single cell analysis technology cellular biochemistry to study autoimmunity, cancer, virology (influenza & Ebola), as well as understanding normal immune system function. Using advanced flow cytometric techniques such as Mass Cytometry, MIBI (ion beam imaging), CODEX and computational biology approaches, we focus on understanding disease processes at the single cell level. We have a strong interest in cancer immunotherapy and pathogen-host interactions.
-
Jeffrey Norton, MD
Robert L. and Mary Ellenburg Professor of Surgery, Emeritus
Current Research and Scholarly InterestsInterleukin-12 is a Th1 cytokine. It is important in the cell mediated immune response. We are investigating its role as an anti-tumor cytokine to augment the immune response against cancer. We are planning a human trial.
-
Roeland Nusse
Virginia and Daniel K. Ludwig Professor of Cancer Research
Current Research and Scholarly InterestsOur laboratory studies Wnt signaling in development and disease. We found recently that Wnt proteins are unusual growth factors, because they are lipid-modified. We discovered that Wnt proteins promote the proliferation of stem cells of various origins. Current work is directed at understanding how Wnt signals lead to the proliferation of stem cells and on understanding Wnt signaling during repair and regeneration after tissue injury.
-
Lucy Erin O'Brien
Associate Professor of Molecular and Cellular Physiology
Current Research and Scholarly InterestsMany adult organs tune their functional capacity to variable levels of physiologic demand. Adaptive organ resizing breaks the allometry of the body plan that was established during development, suggesting that it occurs through different mechanisms. Emerging evidence points to stem cells as key players in these mechanisms. We use the Drosophila midgut, a stem-cell based organ analogous to the vertebrate small intestine, as a simple model to uncover the rules that govern adaptive remodeling.
-
Derick Okwan
Assistant Professor of Pathology
Current Research and Scholarly InterestsBroadly, the Okwan lab’s primary interest is to understand how and why the immune system contributes to nearly all chronic diseases. The immune system of the modern human has evolved from a history of stress to the species: famines, continual bouts of lethal pandemics, as well as major climate/environmental and migratory changes that exposed the immune system to novel threats. At the forefront of these challenges are innate immune cells, particularly neutrophils, the most abundant leukocytes. For the first time in human history – at least in the western world- we live in an era of abundance. The Okwan lab is interested in understanding how this traumatic history creates a functional mismatch for the neutrophil, which we believe underpins their roles in chronic diseases of the modern era: cancer, cardiovascular disease, neurodegeneration, and autoimmune disorders. Rather than wholesale depletion of neutrophils and innate immune cells, we seek to identify novel approaches to leverage these cells to combat various diseases.
-
Anthony Oro, MD, PhD
Eugene and Gloria Bauer Professor
Current Research and Scholarly InterestsOur lab uses the skin to answer questions about epithelial stem cell biology, differentiation and carcinogenesis using genomics, genetics, and cell biological techniques. We have studied how hedgehog signaling regulates regeneration and skin cancer, and how tumors evolve to develop resistance. We study the mechanisms of early human skin development using human embryonic stem cells. These fundamentals studies provide a greater understanding of epithelial biology and novel disease therapeutics.
-
Doug Owens
Henry J. Kaiser, Jr. Professor, Senior Fellow at the Freeman Spogli Institute for International Studies and Professor, by courtesy, of Management Science and Engineering
Current Research and Scholarly InterestsMy research uses decision modeling, cost-effectiveness analysis, and meta-analysis to evaluate clinical and health policy problems. Much of my work involves development of national guidelines for prevention and treatment.
-
Theo Palmer
Professor of Neurosurgery, Emeritus
Current Research and Scholarly InterestsMembers of the Palmer Lab study the biology of neural stem cells in brain development and in the adult. Our primary goal is to understand how genes and environment synergize in influencing stem cell behavior during development and how mild genetic or environmental risk factors for disease may synergize in their detrimental effects on brain development or in the risk of neuronal loss in age-related degenerative disease.
-
Minggui Pan, MD, PhD
Clinical Professor, Medicine - Oncology
BioDr. Pan is a board-certified, fellowship-trained medical oncologist with the Stanford Medicine Cancer Center and a clinical professor in the Department of Medicine, Division of Oncology.
He diagnoses and treats various oncological conditions and specializes in the treatment of bone and soft tissue sarcoma. He creates personalized and comprehensive care plans for each patient he serves.
Dr. Pan’s research focuses include understanding how genomic alterations impact the biological behavior and prognosis of sarcomas. In his work, he identifies new targets for developing innovative therapeutics for sarcoma treatment.
Dr. Pan has more than eighty publications and presented many abstracts in several cancer and immunology conferences. His papers have been published in the Journal of Clinical Oncology, JCO Precision Oncology, Clinical Cancer Research, Nature Review Clinical Oncology, Nature Nanotechnology, Frontier Endocrinology, JCO Oncology Practice, Journal of Hematology and Oncology, British Journal of Cancer Reports, and other peer-reviewed journals. He has also presented to his peers at international, national, and regional meetings, including the annual meetings of American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), European Society for Medical Oncology (ESMO), Chinese Society Of Clinical Oncology (CSCO), Connective Tissue Oncology Society (CTOS) and others.
Dr. Pan is a member of American Society of Clinical Oncology, American Association for Cancer Research, American Association of Immunologists, American Association for Advancement of Science, Society for Immunotherapy of Cancer, and Connective Tissue Oncology Society. Dr. Pan is also an adjunct investigator with Kaiser Permanente Division of Research. -
Peter Parham
Professor of Structural Biology and, by courtesy, of Microbiology and Immunology
Current Research and Scholarly InterestsThe Parham laboratory investigates the biology, genetics, and evolution of MHC class I molecules and NK cell receptors.
-
Walter Park
Associate Professor of Medicine (Gastroenterology and Hepatology)
Current Research and Scholarly InterestsDr. Park's research interests are in the diagnosis and management of pancreatic cysts, acute and chronic pancreatitis. His approach incorporates methods in health services research including the use of observational datasets, cost-effectiveness studies, and the development of clinical cohorts.
-
Julie Parsonnet
George DeForest Barnett Professor of Medicine, Emerita
Current Research and Scholarly InterestsI am an infectious diseases epidemiologist who has done large field studies in both the US and developing countries. We research the long-term consequences of chronic interactions between the human host and the microbial world. My lab has done fundamental work establishing the role of H. pylori in causing disease and understanding its epidemiology. Currently, our research dissects how and when children first encounter microbes and the long term effects of these exposures on health.
-
Chirag Patel, MD, PhD
Member, Cardiovascular Institute
Current Research and Scholarly InterestsNeuro-oncology, Clinical Trials, Tumor Treating Fields (TTFields), Molecular/PET Imaging, Neuroimaging, Immunotherapy, Big Data Analysis
-
John M. Pauly
Reid Weaver Dennis Professor
BioInterests include medical imaging generally, and magnetic resonance imaging (MRI) in particular. Current efforts are focused on medical applications of MRI where real-time interactive imaging is important. Two examples are cardiac imaging, and the interactive guidance of interventional procedures. Specific interests include rapid methods for the excitation and acquisition of the MR signal, and the reconstruction of images from the data acquired using these approaches.
-
Kim Butts Pauly
Professor of Radiology (Radiological Sciences Lab) and, by courtesy, of Electrical Engineering
Current Research and Scholarly InterestsWe are investigating and developing, and applying focused ultrasound in neuromodulation, blood brain barrier opening, and ablation for both neuro and body applications.
-
Christopher K. Payne, MD
Professor of Urology at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsObstetric Fistula Projects:
1. Preoperative ultrasound evaluation to detect ureteric involvement in vesicovaginal fistulas
2. Patient narrative study to identify key medical, social and economic factors that lead to fistula formation
3. Study of urinary continence after fistula repair
Pelvic pain: investigation into role of pelvic floor in chronic pelvic pain -
Donna Peehl, PhD
Professor (Research) of Urology, Emerita
Current Research and Scholarly InterestsMy research focuses on the molecular and cellular biology of the human prostate. Developing realistic experimental models is a major goal, and primary cultures of prostatic epithelial and stromal cells are my main model system. Our discoveries are relevant to prevention, detection, diagnosis and treatment of benign and malignant prostatic diseases.
-
Mark Pegram
Susy Yuan-Huey Hung Professor
On Partial Leave from 03/01/2025 To 11/30/2025Current Research and Scholarly InterestsMolecular mechanisms of targeted therapy resistance in breast and other cancers
-
Norbert Pelc
Boston Scientific Applied Biomedical Engineering Professor and Professor of Radiology, Emeritus
Current Research and Scholarly InterestsBroadly, Dr. Pelc is interested in the physics, engineering and mathematics of medical imaging, especially computed tomography, digital x-ray imaging, magnetic resonance imaging, and hybrid multimodality systems. His current research is concentrated in the development of computed tomography systems with higher image quality and dose efficiency, in the characterization of system performance, and in the development and validation of new clinical applications.
-
VJ Periyakoil, Professor of Medicine
Professor of Medicine (Primary Care and Population Health)
Current Research and Scholarly InterestsMy lab is focused on longevity and healthy aging, multi-cultural palliative care and geriatrics research.
-
Claudia Katharina Petritsch
Associate Professor (Research) of Neurosurgery
Senior Research Scientist, Adult NeurologyCurrent Research and Scholarly InterestsThe Petritsch lab broadly investigates underlying causes for the intra-tumoral heterogeneity and immune suppression in brain tumors from a neuro-developmental perspective. Defective cell fate decisions fuel the intra-humoral heterogeneity and plasticity in human brain tumors and may contribute to immune suppression. We use patient-derived models as avatars to study how brain cells control the fate of their progeny, whereby we unravel novel points of vulnerabilities in brain tumor cells.
-
Dmitri Petrov
Michelle and Kevin Douglas Professor in the School of Humanities and Sciences
Current Research and Scholarly InterestsEvolution of genomes and population genomics of adaptation and variation
-
Suzanne Pfeffer
Emma Pfeiffer Merner Professor of Medical Sciences
On Leave from 10/16/2025 To 01/15/2026Current Research and Scholarly InterestsThe major focus of our research is to understand the molecular basis of inherited Parkinson's Disease (PD). We focus on the LRRK2 kinase that is inappropriately activated in PD and how it phosphorylates Rab GTPases, blocking the formation of primary cilia in specific regions of the brain. The absence of primary cilia renders cells unable to carry out Hedgehog signaling that is critical for neuroprotective pathways that sustain dopamine neurons.
-
Harlan Pinto
Associate Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsClinical Interests: general oncology, head and neck cancer Research Interests: chemoprevention trials and combined modality approaches to head and neck cancer
-
Sharon Pitteri
Professor (Research) of Radiology (Diagnostic Sciences Laboratory)
Current Research and Scholarly InterestsThe Pitteri laboratory is focused on the discovery and validation of proteins that can be used as molecular indicators of risk, diagnosis, progression, and recurrence of cancer. Proteomic technologies, predominantly mass spectrometry, are used to identify proteins in the blood that are differentially regulated and/or post-translationally modified with disease state. Using human plasma samples, tumor tissue, cancer cell lines, and genetically engineered mouse models, the origins of these proteins are being investigated. A major goal of this research is to define novel molecular signatures for breast and ovarian cancers, including particular sub-types of these diseases. This laboratory is also focused on the identification of proteins with expression restricted to the surface of cancer cells which can be used as novel targets for molecular imaging technologies.
-
Philip A. Pizzo, M.D.
David and Susan Heckerman Professor, Emeritus
BioPhilip Pizzo, MD, is the David and Susan Heckerman Professor Emeritus. Pizzo served as Dean of the Stanford School of Medicine from April 2001 to December 1, 2012. He was Founding Director of the Stanford Distinguished Careers Institute from 2012 - 2022. Pizzo began rabbinical studies at the Academy for Jewish Religion, California in 2022 and studies in Spiritual Care and Counseling at the Jewish Theological Seminary in 2024.
Dr. Pizzo career focused on the diagnosis, management, prevention and treatment of childhood cancers and the infectious complications that occur in children whose immune systems are compromised by cancer and AIDS. He has been a leader in academic medicine and in longevity and the future of higher education.
Pizzo received his MD degree with Honors and Distinction in Research from the University of Rochester in 1970 and completed an internship and residency at the Boston Children’s Hospital. He was a fellow in pediatric oncology at the National Cancer Institute (NCI) and served as head of the NCI’s infectious disease section, chief of pediatric oncology, and scientific director for the Division of Clinical Sciences between. Before joining Stanford in 2001, he was the physician-in-chief of Boston Children’s Hospital and Chair of the Department of Pediatrics at Harvard Medical School, where he was also the Thomas Morgan Rotch Professor of Pediatrics.
Dr. Pizzo is the author of more than 650 scientific articles and 16 books and monographs. He also served as Editor-in-Chief of Current Opinion in Pediatrics from 2012 - 2019. He co-led the National Academy of Medicine 2011 report Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research; and “Dying in America: Improving Quality and Honoring Individual Preferences at the End of Life” that was published in 2015.
Pizzo has received numerous awards and honors, including the Public Health Service Outstanding Service Medal in 1995, the Barbara Bohen Pfiefer Award for Scientific Excellence in 1991, the Elizabeth Kubler-Ross Award in 2008, the Ronald McDonald Charities “Award of Excellence” in 2009, and the John and Emma Bonica Public Service Award in 2013. He is the 2012 recipient of the John Howland Award, the highest honor for lifetime achievement bestowed by the American Pediatric Society. In 2019 he received the John Stearns Medal from the New York Academy of Medicine. Pizzo received the 2021 International Immunocompromised Host Society’s Lifetime Distinguished Career Award. He received the Dean’s Medal from the University of Rochester in 2023.
Pizzo has been elected to the Association of American Physicians, the American Society of Clinical Investigation, the American Pediatric Society, the National Academy of Medicine. He has served as Chair of the Association of Academic Health Centers and Chair of the Council of Deans of the Association of American Medical Colleges. He was elected to the Board of Directors of the American Society for Clinical Oncology and the Infectious Diseases Society of America. He was President of the International Immunocompromised Host Society between1998 – 2011, and he served on the Governing Board for the California Institute of Regenerative Medicine from 2004 - 2012. Pizzo was elected to the Board of Trustees of the University of Rochester from 2009 - 2022 and the Board of Overseers of Koc University in Istanbul, Turkey from 2010 - 2022. He served Academic Advisory Council for Merritt Hawkins between 2015 - 2022., and the Advisory Board to the Milken Institute Center on Aging from 2015 - 2022. He was elected to the Board of Directors of the Ludwig Institute for Cancer Research from 2012- 2022. In 2015 Pizzo was elected to the Board of Directors of Global Blood Therapeutics through 2023, and in 2019 he was elected to the Board of Directors of Hillel at Stanford through 2023. -
Sylvia K. Plevritis, PhD
William M. Hume Professor in the School of Medicine, Professor of Biomedical Data Science and of Radiology
Current Research and Scholarly InterestsMy research program focuses on computational modeling of cancer biology and cancer outcomes. My laboratory develops stochastic models of the natural history of cancer based on clinical research data. We estimate population-level outcomes under differing screening and treatment interventions. We also analyze genomic and proteomic cancer data in order to identify molecular networks that are perturbed in cancer initiation and progression and relate these perturbations to patient outcomes.
-
Natalia Plewa Juraszek
Postdoctoral Scholar, Stanford Cancer Institute
BioDr. rer. nat. Natalia Plewa-Juraszek is a postdoc in the Department of Pediatrics at Stanford University School of Medicine in Prof. Sabine Heitzeneder and Prof. Crystal Mackall Labs. She is leading a collaborative project focused on designing cancer-specific T cell-based immunotherapies for pediatric solid tumors. Her 9 years hands-on experience, supported by 8 scholarships, including Fulbright, is dedicated to translating innovative technologies from the lab to patient care. Ownership mindset with strong communication and management skills. Critical thinker living the idea “Follow your heart but take your brain with you”. Outside of science, Natalia is a professional Bachata Sensual Instructor and International Dance Judge who transformed a dance business into a global brand, earning over 70 teaching invitations in 15+ countries worldwide.
-
Jonathan Pollack
Professor of Pathology
Current Research and Scholarly InterestsResearch in the Pollack lab centers on translational genomics, with a focus on prostate diseases. The lab employs next-generation sequencing, single-cell and spatial genomics, gene editing, and human cell/tissue-based modeling to uncover disease mechanisms, biomarkers and therapeutic targets. Current areas of emphasis include benign prostatic hyperplasia, prostate cancer, and rare/neglected cancer types (ameloblastoma, liposarcoma).
-
Matthew Porteus
Sutardja Chuk Professor of Definitive and Curative Medicine
BioDr. Porteus was raised in California and was a local graduate of Gunn High School before completing A.B. degree in “History and Science” at Harvard University where he graduated Magna Cum Laude and wrote an thesis entitled “Safe or Dangerous Chimeras: The recombinant DNA controversy as a conflict between differing socially constructed interpretations of recombinant DNA technology.” He then returned to the area and completed his combined MD, PhD at Stanford Medical School with his PhD focused on understanding the molecular basis of mammalian forebrain development with his PhD thesis entitled “Isolation and Characterization of TES-1/DLX-2: A Novel Homeobox Gene Expressed During Mammalian Forebrain Development.” After completion of his dual degree program, he was an intern and resident in Pediatrics at Boston Children’s Hospital and then completed his Pediatric Hematology/Oncology fellowship in the combined Boston Chidlren’s Hospital/Dana Farber Cancer Institute program. For his fellowship and post-doctoral research he worked with Dr. David Baltimore at MIT and CalTech where he began his studies in developing homologous recombination as a strategy to correct disease causing mutations in stem cells as definitive and curative therapy for children with genetic diseases of the blood, particularly sickle cell disease. Following his training with Dr. Baltimore, he took an independent faculty position at UT Southwestern in the Departments of Pediatrics and Biochemistry before again returning to Stanford in 2010 as an Associate Professor. During this time his work has been the first to demonstrate that gene correction could be achieved in human cells at frequencies that were high enough to potentially cure patients and is considered one of the pioneers and founders of the field of genome editing—a field that now encompasses thousands of labs and several new companies throughout the world. His research program continues to focus on developing genome editing by homologous recombination as curative therapy for children with genetic diseases but also has interests in the clonal dynamics of heterogeneous populations and the use of genome editing to better understand diseases that affect children including infant leukemias and genetic diseases that affect the muscle. Clinically, Dr. Porteus attends at the Lucille Packard Children’s Hospital where he takes care of pediatric patients undergoing hematopoietic stem cell transplantation.
-
George A. Poultsides, MD, MS
Stanford Department of Surgery Professor
Current Research and Scholarly InterestsClinical trials of experimental diagnostics and therapeutics; outcomes analysis following combined modality treatment of hepatic, pancreatic, and gastrointestinal malignancies.
-
Guillem Pratx
Associate Professor of Radiation Oncology (Radiation Physics)
Current Research and Scholarly InterestsThe Physical Oncology Lab is interested in making a lasting impact on translational cancer research by building novel physical tools and methods.
-
Judith Prochaska
Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsDr. Prochaska's research expertise centers on technology-mediated health behavior change interventions including targets of tobacco, physical activity, and dietary change. Working with Alaska Native and Latino communities, people with serious mental illness, alcohol and drug problems, or heart disease, and jobseekers and the unhoused, Dr. Prochaska’s research combines stage-tailored interventions with pharmacotherapy and utilizes interactive expert system interventions and social media.
-
Carla Pugh, MD, PhD
Thomas Krummel Professor
Current Research and Scholarly InterestsThe Technology Enabled Clinical Improvement (T.E.C.I.) Center is a multidisciplinary team of researchers dedicated to the design and implementation of advanced engineering technologies that facilitate data acquisition relating to clinical performance.
-
Lei (Stanley) Qi
Associate Professor of Bioengineering
BioDr. Lei (Stanley) Qi is an Associate Professor in the Department of Bioengineering at Stanford University, an Institute Scholar at Sarafan ChEM-H, and an Investigator at the Chan Zuckerberg Biohub. He earned his B.S. in Physics and Mathematics from Tsinghua University and his Ph.D. in Bioengineering from the University of California, Berkeley. Before joining the Stanford faculty in 2014, Dr. Qi was a Systems Biology Fellow at UCSF.
Dr. Qi is a pioneer in the development of CRISPR technologies for precise genome and epigenome engineering. His lab created the first nuclease-deactivated Cas9 (dCas9) for targeted gene regulation, establishing the fields of CRISPR interference (CRISPRi) and activation (CRISPRa). The Qi lab continues to expand this versatile toolbox, inventing new technologies for multiplexed transcriptome engineering (MEGA), 3D genome manipulation (CRISPR-GO), and live-cell imaging. Recent innovations include Live-FISH and Oligo-LiveFISH, a technology for capturing enhancer-promoter interactions in real-time, and the development of ultra-compact CRISPR systems, culminating in the clinical translation of CasMINI for neuromuscular diseases.
Leveraging this suite of bespoke technologies, Dr. Qi's group makes key discoveries at the intersection of synthetic biology, epigenetics, and medicine. His lab has illuminated the synergistic functions of enhancer elements in cancer, and by using transcriptome perturbation in T cells, has identified novel metabolic pathways that can be targeted to enhance tumor killing. A landmark achievement using CRISPR-TO to manipulate the spatial transcriptome in cortical neurons led to the discovery of novel RNA localization patterns that promote neuronal growth by 50%.
The Qi lab is currently focused on three major research frontiers:
1.Therapeutic epigenome editing: Developing next-generation epigenetic editors as novel therapeutics for modulating the immune system, treating brain disorders, and reversing hallmarks of aging.
2.Functional spatial transcriptomics: Unraveling the functional roles of spatial RNA organization in physiology and disease, and how its misregulation drives pathology.
3.Fundamental genome biology: Deploying advanced live-cell chromatin and RNA imaging and computational tools such as AI and machine learning to understand the first principles governing 3D genome regulation, transcription, and epigenetic memory. -
Stephen Quake
Lee Otterson Professor in the School of Engineering and Professor of Bioengineering, of Applied Physics and, by courtesy, of Physics
Current Research and Scholarly InterestsSingle molecule biophysics, precision force measurement, micro and nano fabrication with soft materials, integrated microfluidics and large scale biological automation.
-
Sneha Ramakrishna
Assistant Professor of Pediatrics (Hematology/Oncology)
BioSneha Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. In medical school, through the Howard Hughes Medical Research Scholar Award, she joined Dr. Crystal Mackall’s laboratory, where she designed and developed various GD2 CAR-Ts and tested them in preclinical models. During her residency training in Pediatrics at the Children’s Hospital of Philadelphia, she cared for some of the first patients treated with CD19 CAR T cells, learning the power of this therapy first-hand. During her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program, she worked with Dr. Terry Fry. She evaluated the mechanism of CD22 CAR T cell relapse in patients by developing an antigen escape model and establishing a deeper understanding of the effects of antigen density on CAR-T phenotype, expansion, and persistence (Fry…Ramakrishna…Mackall Nat Med, 2018; Ramakrishna, et al., Clinical Cancer Research, 2019). Since arriving at Stanford, Dr. Ramakrishna leads an interdisciplinary team that designs, develops, and successfully implements a robust correlative science platform for our novel CAR-T therapies. Analyzing patient samples from our first-in-human GD2 CAR-T trial (NCT04196413) treating a universally fatal cancer, diffuse midline glioma (DMG), we identified that intracerebroventricular CAR-T administration correlates with enhanced pro-inflammatory cytokines and reduced immunosuppressive cell populations in cerebrospinal fluid as compared to intravenous CAR-T administration (Majzner*, Ramakrishna*, et al., Nature 2022 *co-first authors). Her research program evaluates unique sets of patient samples using novel single-cell immune profiling to identify the drivers of CAR-T success or failure. Building on these findings, her team assesses approaches to enhance CAR-T efficacy and translate these findings to the clinic.
Clinically, Dr. Ramakrishna cares for children with solid tumors and treats hematologic, solid, and brain tumor pediatric patients with CAR T cell therapies in the Cancer Cellular Therapies program. -
Kavitha Ramchandran
Clinical Professor, Medicine - Oncology
Current Research and Scholarly InterestsMy research focuses on innovative models of care delivey to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.
In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs. -
Jianghong Rao
Professor of Radiology (Molecular Imaging Program at Stanford) and, by courtesy, of Chemistry
Current Research and Scholarly InterestsProbe chemistry and nanotechnology for molecular imaging and diagnostics
-
Lawrence Recht, MD
Professor of Neurology and Neurological Sciences (Adult Neurology) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsOur laboratory focuses on two interrelated projects: (1) assessment of glioma development within the framework of the multistage model of carcinogenesis through utilization of the rodent model of ENU neurocarcinogenesis; and (2) assessment of stem cell specification and pluripotency using an embryonic stem cell model system in which neural differentiation is induced.
-
David Rehkopf
Professor of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Pediatrics, of Health Policy and of Sociology
BioI am a social epidemiologist and serve as a Professor in the Department of Epidemiology and Population Health and in the Department of Medicine in the Division of Primary Care and Population Health. I joined the faculty at Stanford School of Medicine in 2011.
I am Director of the Stanford Center for Population Health Sciences. In this position, I am committed to making high-value data resources available to researchers across disciplines in order to better enable them to answer their most pressing clinical and population health questions.
My own research is focused on understanding the health implications of the myriad decisions that are made by corporations and governments every day - decisions that profoundly shape the social and economic worlds in which we live and work. While these changes are often invisible to us on a daily basis, these seemingly minor actions and decisions form structural nudges that can create better or worse health at a population level. My work demonstrates the health implications of corporate and governmental decisions that can give the public and policy makers evidence to support new strategies for promoting health and well-being. In all of his work, I have a focus on the implications of these exposures for health inequalities.
Since often policy and programmatic changes can take decades to influence health, my work also includes more basic research in understanding biological signals that may act as early warning signs of systemic disease, in particular accelerated aging. I examine how social and economic policy changes influence a range of early markers of disease and aging, with a particular recent focus on DNA methylation. I am supported by several grants from the National Institute on Aging and the National Institute on Minority Health and Health Disparities to develop new more sensitive ways to understand the health implications of social and economic policy changes. -
David A. Relman
Thomas C. and Joan M. Merigan Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsMy investigative program focuses on human-microbe interactions and human microbial ecology, and primarily concerns the ecology of human indigenous microbial communities; a secondary interest concerns the classification of humans with systemic infectious diseases, based on features of genome-wide gene transcript abundance patterns and pther aspects of the host response.
-
Nathan Reticker-Flynn, PhD
Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsTo metastasize throughout our bodies, tumors subvert and co-opt our immune systems. Our lab seeks to uncover how these processes occur and develops therapies to put a stop to them.
-
Andrew Rezvani, M.D.
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsClinical research in allogeneic hematopoietic cell transplantation
-
Thomas Robinson
The Irving Schulman, M.D. Professor of Child Health, Professor of Medicine (Stanford Prevention Research Center) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsDr. Robinson originated the solution-oriented research paradigm and directs the Stanford Solutions Science Lab. He is known for his pioneering obesity prevention and treatment research, including the concept of stealth interventions. His research applies social cognitive models of behavior change to behavioral, social, environmental and policy interventions for children and families in real world settings, making the results relevant for informing clinical and public health practice and policy.
-
William H. Robinson, MD PhD
James W. Raitt, M.D. Professor
Current Research and Scholarly InterestsOur lab investigates the molecular mechanisms of and develops therapies to treat autoimmune and rheumatic diseases, with a focus on rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and osteoarthritis.
The overriding objectives of our laboratory are:
1. To elucidate the mechanisms underlying autoimmune and rheumatic diseases.
2. To investigate the role of innate immune inflammation in osteoarthritis.
3. To develop novel diagnostics and therapeutics -
Stanley G. Rockson, MD
Allan and Tina Neill Professor of Lymphatic Research and Medicine
Current Research and Scholarly InterestsMy clinical research includes studies on risk factor modification in atherosclerosis and coronary artery disease; clinical trials involving medical therapies for peripheral arterial insufficiency; coronary angiogenesis; therapy of lymphedema; atherand photodynamic therapy in atherosclerosis.
-
Kacper Rogala
Assistant Professor of Structural Biology and of Chemical and Systems Biology
Current Research and Scholarly InterestsOur team is fascinated by how cells make growth decisions — to grow or not to grow. In order to grow, cells require nutrients, and we are unraveling how cells use specialized protein sensors and transporters to sense and traffic nutrients in between various compartments. We use approaches from structural biology, chemical biology, biophysics, biochemistry, and cell biology — to reveal the mechanisms of basic biological processes, and we develop chemical probes that modulate them.
-
Rajat Rohatgi
Professor of Biochemistry and of Medicine (Oncology)
Current Research and Scholarly Intereststhe overall goal of my laboratory is to uncover new regulatory mechanisms in signaling systems, to understand how these mechanisms are damaged in disease states, and to devise new strategies to repair their function.
-
Maria Grazia Roncarolo
George D. Smith Professor of Stem Cell and Regenerative Medicine, Emerita
Current Research and Scholarly InterestsResearch Interests
Immunetolerance: Mechanisms underlying T-cell tolerance, induction of T-cell anergy and regulatory T cells; Immunomodulation: mAbs, proteins and low molecular weight compounds which can modulate T-cell activation; Primary immunodeficiencies: Characterization of molecular and immunological defects; Gene therapy: Gene transduction of hematopoietic cells for gene therapy in primary immunodeficiencies and metabolic diseases; Hematopoiesis: Mechanisms underlying growth and differentiation of hematopoietic stem cells; Transplantation: Immune reconstitution and T-cell tolerance after allogenic stem cell transplantation; Cytokines/Cytokine receptors: Role in regulation of immune and inflammatory responses
Clinical Interests
Primary Immunodeficiencies
Monogenic Autoimmune Disorders
Allogenic Bone Marrow Transplantation
Gene Therapy Clinical Trials
Cell Therapy Clinical Trials
Clinical Trials in Autoimmune Diseases and Organ Transplantation
Clinical Trials in Hemoglobinopathies -
Lisa Goldman Rosas
Associate Professor (Research) of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Pediatrics
BioLisa Goldman Rosas, PhD MPH is an Associate Professor in the Department of Epidemiology and Population Health and the Department of Medicine, Division of Primary Care and Population Health at Stanford School of Medicine. An epidemiologist by training, Dr. Goldman Rosas’ research focuses on addressing disparities in diet-related chronic diseases such as diabetes, heart disease, depression, and cancer especially for those who face food insecurity. This research features rigorous quantitative and qualitative methodologies, participatory qualitative approaches, and shared leadership with patient and community partners. She is passionate about integrating patients, caregivers, community organizations, and other key stakeholders in the research process in order to affect the greatest improvements in health and well-being. As a reflection of this passion, Dr. Goldman Rosas serves as the Faculty Director for the School of Medicine Office of Community Engagement, Co-Director of Community-Engaged Research for the Office of Cancer Health Equity, and Director of the Outreach, Recruitment and Engagement Core for the Alzheimer's Disease Research Center. In these roles, she supports other faculty and patient and community partners to develop sustainable and meaningful partnerships to support transformative research. In addition to research, she teaches at the undergraduate and graduate levels and has a special focus on increasing capacity in community engagement methods.
-
David Rosenthal
Professor of Pediatrics (Pediatric Cardiology)
On Partial Leave from 10/06/2025 To 11/07/2025Current Research and Scholarly InterestsResearch interests include the study of Heart Failure, Cardiomyopathy and ventricular dysfunction in children, from a clinical perspective. Investigations include clinical trials of medications, cardiac resynchronization, and mechanical circulatory support.
-
Jason B. Ross, MD, PhD
Assistant Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy laboratory studies studying normal, dysfunctional, and malignant stem cells in the context of aging, cancer, and cancer therapies.
-
Theodore Roth
Assistant Professor of Pathology
Current Research and Scholarly InterestsThe Roth Lab develops, applies, and translates scalable genetic manipulation technologies in primary human cells and complex in vivo tissue environments. Working with students, trainees, and staff with backgrounds across bioengineering, genetics, immunology, oncology, and pathology, the lab has developed CRISPR-All, a unified genetic perturbation language able to arbitrarily and combinatorially examine genetic perturbations across perturbation type and scale in primary human cells. Ongoing applications of CRISPR-All in the lab have revealed surprising capacities to synthetically engineer human cells beyond evolved cellular states. These new capacities to perturb human cell’s genetics beyond their evolved functionality drives ongoing work to understand the biology and therapeutic potential of synthetic cell state engineering - in essence learning how to build new human genes tailor made for a specific cell and specific environment to drive previously inaccessible therapeutic cellular functions.
-
Daniel Rubin
Professor of Biomedical Data Science and of Radiology (Integrative Biomedical Imaging Informatics at Stanford), Emeritus
Current Research and Scholarly InterestsMy research interest is imaging informatics--ways computers can work with images to leverage their rich information content and to help physicians use images to guide personalized care. Work in our lab thus lies at the intersection of biomedical informatics and imaging science.
-
Mirabela Rusu
Assistant Professor of Radiology (Integrative Biomedical Imaging Informatics) and, by courtesy, of Biomedical Data Science and of Urology
Current Research and Scholarly InterestsDr. Mirabela Rusu focuses on developing analytic methods for biomedical data integration, with a particular interest in radiology-pathology fusion. Such integrative methods may be applied to create comprehensive multi-scale representations of biomedical processes and pathological conditions, thus enabling their in-depth characterization.
-
Raya Saab
Lindhard Family Professor of Pediatric Cancer Biology
BioOur laboratory focuses on investigating molecular mechanisms of oncogene-induced tumorigenesis and tumor suppressor pathways, and oncogenic signaling in the pediatric solid tumor rhabdomyosarcoma. Our earlier work identified the tumor suppressors p53 and p18Ink4c as inhibitors of Cyclin D1-driven tumorigenesis in a pineoblastoma model, through senescence induction, and highlighted distinct roles for the the RB and p53 pathways in induction and maintenance of oncogene-induced senescence. We also identified CDK2 as a potential target for inducing senescence in premalignant lesions to inhibit tumor progression.
Our current focus is on studying oncogenic signaling and tumor suppression in the childhood tumor rhabdomyosarcoma, to identify key mediators of invasion and metastasis, which is the most common cause of treatment failure clinically. We use preclinical in vitro and in vivo models, including murine and human cell lines, and mouse models of disease.
We have recently uncovered a paracrine role for rhabdomyosarcoma-secreted exosomes in impacting biology of stromal cells. Rhabdomyosarcoma-derived exosomes carry specific miRNA cargo that imparts an invasive and migratory phenotype on normal recipient fibroblasts, and proteomic analysis revealed specific and unique pathways relevant to the two different molecular rhabdomyosarcoma subtypes that are driven by distinct oncogenic pathways. We identified that the driver oncogene in fusion-positive rhabdomyosarcoma, PAX3-FOXO1, modulates exosome cargo to promote invasion, migration, and angiogenic properties, and identified specific microRNA and protein cargo acting as effectors of PAX3-FOXO1 exosome-mediated signaling, including modulation of oxidative stress response and cell survival signaling.
Our ongoing work is focused on interrogating specific paracrine signaling pathways and molecular mechanisms of metastatic disease progression in rhabdomyosarcoma, for potential therapeutic targeting. -
Chiara Sabatti
Professor of Biomedical Data Science and of Statistics
On Leave from 10/01/2025 To 03/27/2026Current Research and Scholarly InterestsStatistical models and reasoning are key to our understanding of the genetic basis of human traits. Modern high-throughput technology presents us with new opportunities and challenges. We develop statistical approaches for high dimensional data in the attempt of improving our understanding of the molecular basis of health related traits.
-
Julien Sage
Elaine and John Chambers Professor of Pediatric Cancer and Professor of Genetics
Current Research and Scholarly InterestsWe investigate the mechanisms by which normal cells become tumor cells, and we combine genetics, genomics, and proteomics approaches to investigate the differences between the proliferative response in response to injury and the hyperproliferative phenotype of cancer cells and to identify novel therapeutic targets in cancer cells.
-
Kathleen M. Sakamoto
Shelagh Galligan Professor in the School of Medicine
Current Research and Scholarly InterestsMy research focuses on the molecular pathways that regulate normal and aberrant blood cell development, including acute leukemia and bone marrow failure syndromes. We are also studying novel drugs for treatment of cancer.
-
Julia Salzman
Associate Professor of Biomedical Data Science, of Biochemistry and, by courtesy, of Statistics and of Biology
On Leave from 09/01/2025 To 06/01/2026Current Research and Scholarly Interestsstatistical computational biology focusing on splicing, cancer and microbes
-
Serena Sanulli
Assistant Professor of Genetics
Current Research and Scholarly InterestsWe study the organizing principles of the genome and how these principles regulate cell identity and developmental switches. We combine Biochemistry and Biophysical methods such as NMR and Hydrogen-Deuterium Exchange-MS with Cell Biology, and Genetics to explore genome organization across length and time scales and understand how cells leverage the diverse biophysical properties of chromatin to regulate genome function.
-
Kavita Sarin, MD, PhD
Professor of Dermatology
Current Research and Scholarly InterestsMy research encompasses two main areas: 1) Using next-generation RNA, whole genome, and exome sequencing, we are investigating the genetic alterations involved in skin cancer progression, response to therapy, and other clinical outcomes and 2) We are developing and implementing genome-wide genetic risk prediction assessments for skin cancer into clinical use and studying the impact of this information on patient care.
-
Peter Sarnow
Burt and Marion Avery Professor of Immunology
Current Research and Scholarly InterestsOur laboratory studies virus-host interactions with an emphasis microRNA-mediated gene regulation and on translational control. The mechanism by which a liver-specific microRNA regulates hepatitis C virus genome replication is under intense scrutiny. In addition, the mechanism of internal ribosome entry in certain cellular and viral mRNAs and its biological role in growth and development is being investigated.
-
Ansuman Satpathy
Associate Professor of Pathology
Current Research and Scholarly InterestsOur lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, we are leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). We are also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.
-
Lidia Schapira
Professor of Medicine (Oncology)
BioDr. Schapira is a medical oncologist with clinical expertise in the treatment of breast cancer. As the inaugural Director of Stanford's Cancer Survivorship Program, she has developed a thriving research and clinical program focused on optimizing health outcomes for people living with and beyond cancer. Dr. Schapira is interested in training future generations of physician-scientists as well as the broader community of practicing physicians through the design of innovative educational programs. Dr. Schapira's advocacy for people with cancer led to her appointment as Editor-in-Chief of the American Society of Clinical Oncology's website for the public,Cancer.Net, a position she held from 2015 until-2021. She served on the Board of Directors of the American Psychosocial Oncology Society and as Chair of the Psychosocial Interest Group of the Multinational Society for Supportive Care in Cancer. Dr. Schapira is particularily committed to reducing inequities in cancer outcomes and improve access to cancer care and cancer clinical trials. Dr. Schapira has published numerous manuscripts, lectures both nationally and internationally on issues of cancer survivorship and served as Associate Editor of the narrative section, Art of Oncology, for the Journal of Clinical Oncology from 2013 until 2023.
-
Gary Schoolnik
Professor of Medicine (Infectious Diseases), Emeritus
Current Research and Scholarly InterestsStructure-function analysis of bacterial adhesion proteins and toxins; design and synthesis of synthetic antigens; immunobiology of human papillomaviruses
-
Liora Schultz
Clinical Associate Professor, Pediatrics - Hematology & Oncology
Affiliate, Pediatrics - Hematology/OncologyBioI am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.
-
Deborah Sellmeyer
Clinical Professor, Medicine - Endocrinology, Gerontology, & Metabolism
BioDr. Sellmeyer is an internationally recognized expert in Metabolic Bone Disease. She is a renowned clinician who joined the Stanford faculty in 2018 as a Professor of Medicine. She has been recognized for her clinical excellence with induction into the Miller Coulson Academy of Clinical Excellence while she was at Johns Hopkins. In addition to her clinical expertise, Dr. Sellmeyer maintains a research program that centers on the effect of nutrition and environmental factors on skeletal metabolism which she has investigated through both smaller CRC-based trials and large multi-center trials. Studies she has conducted have investigated the role of dietary sodium chloride, source of dietary protein (animal, vegetable, dairy, soy), role of dietary potassium and alkaline potassium salts, targeted thoracic exercises on kyphosis, whether structured exercise can prevent bone loss in premenopausal women treated for breast cancer, and studies validating nutritional assessment questionnaires. Her expertise as a clinical researcher has enabled development of a multi-disciplinary translational research team including basic scientists in the orthopedic department, junior faculty members with K grant funding, and basic scientists in the endocrine division to develop translational projects studying the effects of osteoporosis medications on basic elements of skeletal biology utilizing bone biopsies from treated individuals as well as clinical trials of novel therapies for rare bone disorders. Dr. Sellmeyer also is a esteemed educator, having received multiple teaching awards.
-
Kawin Setsompop
Professor of Radiology (Radiological Sciences Laboratory) and, by courtesy, of Electrical Engineering
BioKawin Setsompop is a Professor of Radiology and, by courtesy, of Electrical Engineering. His research focuses on the development of novel MRI acquisition methods, with the goal of creating imaging technologies that can be used to help better understand brain structure and function for applications in Healthcare and Health sciences. He received his Master’s degree in Engineering Science from Oxford University and his PhD in Electrical Engineering and Computer Science from MIT. Prior to joining Stanford, he was a postdoctoral fellow and subsequently a faculty at the A.A. Martinos center for biomedical imaging, MGH, as well as part of the Harvard and MIT faculty. His group has pioneered several widely-used MRI acquisition technologies, a number of which have been successfully translated into FDA-approved clinical products on Siemens, GE, Phillips, United Imaging and Bruker MRI scanners worldwide. These technologies are being used daily to study the brain in both clinical and neuroscientific fields.
-
Ross Shachter
Associate Professor of Management Science and Engineering
Current Research and Scholarly InterestsProf. Shachter's research has focused on the representation, manipulation, and analysis of uncertainty and probabilistic reasoning in decision systems. As part of this work, he developed the DAVID influence diagram processing system for the Macintosh. He has developed models scheduling patients for cancer follow-up, and analyzing vaccination strategies for HIV and Helobacter pylori.
-
Nigam H. Shah, MBBS, PhD
Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science
Current Research and Scholarly InterestsWe answer clinical questions using aggregate patient data at the bedside. The Informatics Consult Service (https://greenbutton.stanford.edu/) put this idea in action and led to the creation of Atropos Health. We build predictive models that allow taking mitigating actions, keeping the human in the loop.
-
Sumit Shah
Clinical Associate Professor, Medicine - Oncology
Clinical Associate Professor (By courtesy), UrologyBioDr. Sumit Shah specializes in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. He also serves as an investigator on numerous clinical trials, with a focus on novel immunotherapy agents. His academic interests also include digital health technologies and novel healthcare delivery services, both in the domestic and international setting. Dr. Shah graduated with distinction in biomedical engineering from Duke University, received his medical doctorate from Stanford University, and Masters in Public Health from Harvard University. He completed his internal medicine residency at the University of California, San Francisco (UCSF) where he stayed on faculty for one year before returning to Stanford for his fellowship training in medical oncology, where he now serves on the faculty.
